PROTEOWISE, INC.

New Haven, CT · Founded 2018 · CIK 0001807738 · Medtech · Private

Microfluidic polyacrylamide electrophoresis (mPAGE) instrument for multiplexed protein analysis

Grants
$252K
1 award
Sector median: 1
Raised
$11M
3 Form D · Dec 2024
22 months since last filing
Contracts
—
No federal contracts on record
Patents
4
1 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,295,940
Federal grantDepartment of Health and Human Services · Phase I · Development of a tool to examine proteomic pathways in the AD brain$251,944
Private capital raisedForm D · SEC$2,653,558
Private capital raisedForm D · SEC$2,306,020
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1195MARS Bioimaging Ltd—$2.0M
1196Medluidics LLC——
1197PathSpot Technologies, Inc.—$3.7M
1198PROTEOWISE, INC.—$11M
1199Pathr.ai, Inc.—$7.3M
1200NexEos Diagnostics, Inc—$26M
1201AXON MEDICAL, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Benjamin CombDirector
  • Erik GuntherDirector · Executive Officer · Promoter
  • David SmollerDirector
  • Daniel WagnerDirector

Patents

USPTO · 1 granted of 4
  • Biological Sample Capture With Multiplex Analysisapplication
  • Biological Sample Capture With Multiplex Analysisgranted
  • Biological Sample Capture With Multiplex Analysisapplication
  • Biological Sample Capture With Multiplex Analysisapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.